DOP033. Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort | Zendy

AI Assistant Blog Pricing

DOP033. Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.